—————————————————————————————————————————————————————————————————————

References

  1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
  2. Kaplan NM. Resistant hypertension. J Hypertens 2005;23:1441-1444.
  3. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345:479-486.
  4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
  5. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac organ damage in refractory hypertension. J Hypertens 2001;19:2063-2070.
  6. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005;18:619-626.
  7. Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165:161-168.
  8. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95.
  9. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001;38:1112-1117.
  10. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996;27:481-490.
  11. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004;17:904-910.
  12. Modan M, Almog S, Fuchs Z, Chetrit A, Lusky A, Halkin H. Obesity, glucose intolerance, hyperinsulinemia, and response to antihypertensive drugs. Hypertension 1991;17:565-573.
  13. Wofford MR, King DS, Wyatt SB, Jones DW. Secondary hypertension: detection and management for the primary care provider. J Clin Hypertens (Greenwich) 2000;2:124-131.
  14. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994;12:609-615.
  15. Omvik P. How smoking affects blood pressure. Blood Press 1996;5:71-77.
  16. Jee SH, He J, Whelton PK, Suh I, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33:647-652.
  17. Graves JW, Bloomfild RL, Buckalew VM Jr. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am J Med Sci 1989;298:361-365.
  18. Hermida RC, Ayala DE, Calvo C, et al. Effects of time of day to treatment of ambulatory blood pressure pattern of patient with resistant hypertension. Hypertension. 2005;46(4):1053-1059.
  19. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002;39:982-988.
  20. Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007;16:80-86.
  21. Moser M, Setaro JF. Clinical practice: Resistant or difficult-to-control hypertension. N Engl J Med 2006;355:385-392.
  22. Pimenta E, Gaddam KK, Oparil S. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich) 2008;10:239-244.
  23. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-358.
  24. Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich) 2005;7:354-356.
  25. Khanna A, Lefkowitz L, White WB. Evaluation of recent fixed-dose combination therapies in the management of hypertension. Curr Opin Nephrol Hypertens 2008;17:477-483.
  26. Dickson M, Plauschinat CA. Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: fixed-dose vs free-combination treatment. Ethn Dis 2008;18:204-209.
  27. Pantelis A Sarafidins, George L Bakris. Resistant Hypertension: An Overview of Evaluation and Treatment. JACC;2008: 52:1749-1757.
  28. Gashti CN, Bakris GL. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens 2004;13:155-161.
  29. Stergiou GS, Makris T, Papavasiliou M, Efstathiou S, Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy .J Hypertens 2005;23:883-889.
  30. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:e510-e526.
  31. Pimenta E, Gaddam KK, Oparil S. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich) 2008;10:239-244.
  32. Trewet CL, Ernst ME. Resistant hypertension: identifying causes and optimizing treatment regimens. South Med J 2008;101:166-173.
  33. Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens 2002;15:583-589.
  34. Hypertension.2008;51;1403-1419.
767
  www.orion-group.net/journals

  www.orion-group.net/medicaljournal
Volume 33, Issue 2, May 2010